Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anavex Life Sciences

9.48
-0.0900-0.94%
Post-market: 9.31-0.1730-1.82%19:53 EDT
Volume:2.82M
Turnover:26.72M
Market Cap:809.33M
PE:-17.05
High:9.78
Open:9.66
Low:9.28
Close:9.57
Loading ...

Jim Cramer on Anavex Life Sciences Corp. (AVXL): ‘It’s A Good Spec’

Insider Monkey
·
31 Jan

Anavex put volume heavy and directionally bearish

TIPRANKS
·
29 Jan

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
28 Jan

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Jan

Anavex Life Sciences Announces Issuance of Blarcamesine (Anavex®2-73) Composition of Matter U.S. Patent Expanding Its Intellectual Property Portfolio

THOMSON REUTERS
·
27 Jan

Anavex Life Sciences Stock Skyrockets 95% in 3 Months: Here's Why

Zacks
·
24 Jan

Anavex Life Sciences Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
21 Jan

New Strong Buy Stocks for January 21st

Zacks
·
21 Jan

Anavex Life Sciences Shares Rise After Positive Trial Results for Alzheimer's Treatment

Dow Jones
·
16 Jan

Anavex Life Sciences Is Maintained at Buy by D. Boral Capital

Dow Jones
·
16 Jan

BRIEF-Anavex Life Sciences Announces Peer-Reviewed Publication Of Oral Blarcamesine Phase Iib/Iii Data In The Journal Of Prevention Of Alzheimer’S Disease

Reuters
·
15 Jan

Anavex announces peer-reviewed publication Phase IIb/III data on blarcamesine

TIPRANKS
·
15 Jan

Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase Iib/Iii Data in the Journal of Prevention of Alzheimer’s Disease

THOMSON REUTERS
·
15 Jan

BRIEF-New Phase IIB/III Clinical Data Demonstrates Over Three Years Of Continuous Treatment With Oral Blarcamesine To Significantly Benefit Early Alzheimer’S Disease Patients

Reuters
·
13 Jan

New Phase Iib/Iii Clinical Data Demonstrates Over Three Years of Continuous Treatment With Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients

THOMSON REUTERS
·
13 Jan

Anavex Life Sciences Corp: Blarcamesine Exhibited a Favorable Safety Profile With No Treatment-Related Deaths

THOMSON REUTERS
·
13 Jan

Anavex Life Sciences Corp: Topline Attention-Ad Trial: Patients Showed Improved Cognition and Function Over Three Years

THOMSON REUTERS
·
13 Jan

Anavex Life Sciences (AVXL) Alzheimer Treatment Sends the Stock to New Heights

TIPRANKS
·
06 Jan

Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?

Zacks
·
31 Dec 2024

All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to Buy

Zacks
·
31 Dec 2024